Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis

Obstetrics and Gynecology

Volumn 122, Issue 1, 2013, Pages 139-147

  Havrilesky, Laura J ^a   Moorman, Patricia G ^b   Lowery, William J ^b   Gierisch, Jennifer M ^b   Coeytaux, Remy R ^b   Urrutia, Rachel Peragallo ^b   Dinan, Michaela ^b   McBroom, Amanda J ^b   Hasselblad, Vic ^b   Sanders, Gillian D ^b   Myers, Evan R ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CASE CONTROL STUDY; COCHRANE LIBRARY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONSENSUS; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MEGADOSE; EMBASE; HUMAN; LOW DRUG DOSE; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; ORAL CONTRACEPTION; OVARY CANCER; PREGNANCY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

CONTRACEPTIVES, ORAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; PREGNANCY; PRIMARY PREVENTION; RISK; RISK MANAGEMENT;

EID: 84880571047     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318291c235     Document Type: Review

References (23)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Amionu R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda (MD): National Cancer Institute; 2010. Available at: http://seer.cancer.gov/csr/1975-2007/. Retrieved February 16, 2011.
2. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630-9.
3. Jacobs I, Skates S, Macdonald N. Ovarian cancer screening was feasible but did not decrease incidence of index cancer or mortality. West J Med 2000;172:97.
4. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
5. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
6. van Nagell JR Jr, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350-6.
7. van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 2007;109:1887-96.
8. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295-303.
9. Moyer VA, U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2012;157:900-4.
10. Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-14.
11. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369:1703-10.
12. Bosetti C, Negri E, Trichopoulos D, Franceschi S, Beral V, Tzonou A, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002;102:262-5.
13. Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991;49:61-5.
14. Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Peragallo Urrutia R, Lowery WJ, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Report #101. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I). AHRQ Publication No. 13-EHC033-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2013. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Retrieved April 19, 2013.
15. Agency for Healthcare Research and Quality. Methods guide for effectiveness and comparative effectiveness reviews. AHRQ Publication No. 10(12)-EHC063-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2012. Available at: www. effectivehealthcare.ahrq.gov. Retrieved April 19, 2013.
16. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis version 2. Englewood (NJ): Biostat; 2005.
17. Schwartz U, Hammerstein J. The estrogenic potency of ethinylestradiol and mestranol - a comparative study. Acta Endocrinol Suppl (Copenh) 1973;173:118.
18. Bolt HM, Bolt WH. Pharmacokinetics of mestranol in man in relation to its oestrogenic activity. Eur J Clin Pharmacol 1974;7: 295-305.
19. National Cancer Institute. Surveillance research - cancer control and population sciences. DevCan: probability of developing or dying of cancer. Available at: http://surveillance.cancer.gov/devcan/. Retrieved January 3, 2013.
20. Centers for Disease Control and Prevention. National Survey of family growth. 2006-2010 NSFG: Public use data files, codebooks, and documentation. Available at: http://www.cdc.gov/nchs/nsfg/nsfg-2006-2010-puf.htm. Retrieved January 3, 2013.
21. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996;94:483-9.
22. Dickey RP, Stone SC. Progestational potency of oral contraceptives. Obstet Gynecol 1976;47:106-12.
23. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.